Cargando…
Case Report: New Onset Lymphadenopathy After Immune Checkpoint Inhibitor Therapy Presents a Clinicopathological and Radiological Challenge
The use of immune-checkpoint inhibitor (ICI) therapy has significantly improved patient outcomes in a wide variety of cancers and has become a cornerstone in the treatment of renal cell carcinoma. However, ICI treatment has the potential to cause a variety of immune-related adverse events (irAEs) th...
Autores principales: | Scarlotta, Matthew, Avery, Robin, Baraban, Ezra, Maleki, Zahra, Ged, Yasser |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165714/ https://www.ncbi.nlm.nih.gov/pubmed/35669423 http://dx.doi.org/10.3389/fonc.2022.876797 |
Ejemplares similares
-
Metastasis to the Bladder: A Rare Site of Recurrence of Renal Cell Carcinoma
por: Smart, Amanda, et al.
Publicado: (2022) -
Appendiceal adenocarcinoma presenting as a bladder tumor
por: Goddard, Briana, et al.
Publicado: (2022) -
Adult-Onset Still’s Disease With Extensive Lymphadenopathy Mimicking Lymphoproliferative Malignancy
por: Paul, Mishouri, et al.
Publicado: (2021) -
Plasma cell variant of Castleman lymphadenopathy presenting as an adrenal mass
por: Mindiola-Romero, Andres E., et al.
Publicado: (2021) -
Sarcoidosis: a diagnostic challenge in atypical radiologic findings of unilateral lymphadenopathy
por: Meillier, Andrew, et al.
Publicado: (2015)